Back

Clinical validation of an HPV whole genome sequencing assay for molecular residual disease detection in HPV-associated head and neck cancer patients treated with surgery

2025-11-27 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundSurgery is a common treatment for early-stage HPV-associated head and neck squamous cell carcinoma (HPV+HNC). Selection of patients who require adjuvant treatment is based on clinicopathologic risk factors, which have poor individualized prognostic capacity. Circulating tumor HPV DNA (ctHPVDNA) is a highly sensitive and specific biomarker for HPV+HNC at diagnosis, but current clinically available assays lack the necessary sensitivity for accurate minimal residual disease (MRD) detectio...

Predicted journal destinations